Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MBIO vs NVO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

NVO Overall Winner 6-Pillar Tally: MBIO 0 – 6 NVO Matrix Metrics: MBIO 1 – 9 NVO

As of Nov 17, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas NVO carries 35.1/100 (SELL) at $41.60 (12.5x Forward P/E, 50.8% operating margin).

  • Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. NVO 35.1/100 SELL), NVO captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (50.8% vs. 0.0% operating margin) and revenue trajectory (+5.6% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBIO vs NVO
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.68β · 87% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44
NVO NYSE Head-to-Head Winner
Novo-Nordisk A/S
Pharmaceutical Preparations
$41.60
-0.07% 1D
Market Cap $183.5B
TTM Revenue $51.5B
Forward P/E 12.5x
Beta / 30D Vol 0.50β · 32% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 37.0 Fund 48.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 57.8 · SMA20: $40.13 · SMA50: $39.99

6-Pillar Scorecard Institutional Category Breakdown (MBIO 0 – 6 NVO)

Columns: Metric · MBIO · NVO
1. Valuation Multiples NVO
Forward P/E N/M 12.5x
Trailing P/E N/M 10.5x
PEG Ratio N/M 4.31x
EV / Revenue N/M 3.8x
2. Growth & Scale NVO
Revenue Growth (YoY) +0.0% +5.6%
Earnings Growth (YoY) +0.0% -15.8%
TTM Revenue (USD) N/A $51.5B
Market Cap $3.2M $183.5B
3. Profitability & Quality NVO
Gross Margin N/A 83.3%
Operating Margin 0.0% 50.8%
Net Profit Margin 0.0% 33.9%
Return on Equity (ROE) -43.1% 58.4%
4. Balance Sheet & Cash Flow NVO
Cash Generation (TTM) N/A $6.94B
Cash Flow Margin N/A 13.5%
Net Cash / Leverage $0.87 Book/Sh · -43.1% ROE $13.9B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) 4.32%
5. Options & Positioning NVO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 36.7% (32nd %ile)
Put/Call OI Skew N/A 0.87x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat NVO
OpEx & R&D Intensity N/A 32.5% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Global GLP-1 Diabetes & Obesity Biologics Leader

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBIO (1) vs NVO (9)
Institutional Metric MBIO NVO Criterion Row Edge
Market Capitalization
Scale
$3.2M $183.5B Larger Scale NVO
Trailing P/E Ratio
Valuation
N/M 10.5x Lower Multiple NVO
Forward P/E Ratio
Valuation
N/M 12.5x Lower Multiple NVO
Revenue Growth (YoY)
Growth
+0.0% +5.6% Higher Growth NVO
Operating Margin (TTM)
Profitability
0.0% 50.8% Higher Margin NVO
Net Profit Margin
Profitability
0.0% 33.9% Higher Margin NVO
Return on Equity (ROE)
Capital Efficiency
-43.1% 58.4% Higher ROE NVO
52-Week Range Position
Momentum
3% ($0–$1) 22% ($35–$64) Stronger Trend NVO
Beta / 30D Volatility
Risk Regime
0.68β · 87% Vol 0.50β · 32% Vol Lower Realized Risk NVO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 35.1 / 100 (SELL) Higher Composite MBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $51.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 83.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 4.31x PEG · 3.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.87 Book/Sh · -43.1% ROE) $6.94B ($13.9B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVO +2.27 pp
MBIO: +4.86% · NVO: +7.13%
3M Horizon NVO +21.76 pp
MBIO: -30.75% · NVO: -8.99%
6M Horizon NVO +27.94 pp
MBIO: -33.99% · NVO: -6.05%
1Y Horizon NVO +53.85 pp
MBIO: -67.65% · NVO: -13.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs NVO. Trailing 12-month operating profitability (MBIO 0.0% vs NVO 50.8%) and valuation multiples (MBIO N/M vs NVO 12.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M
NVO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$51.5B
Gross Margin83.3%
Op. Margin50.8%
ROE / Fwd P/E58.4% · 12.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVO CONSOLIDATION
95d in phase · OBV NEUTRAL
Current IV 36.7%
IV Percentile 32nd %ile
Put/Call OI Skew 0.87x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $41.60 · IV 32.0%

NVO Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($4,160)

Compare $4,160 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 32.0% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $42.5 / $45 Bull Call Spread

Buy 1x $42.5C · Sell 1x $45C · 32d

Net Entry $76 Debit
T+5d @ +5% Move +$48 (+63%)
Max Risk / Buffer $76 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $40 / $37.5 Bull Put Spread

Sell 1x $40P · Buy 1x $37.5P · 32d

Net Entry $54 Credit
Max Credit / Yield +$54 (+27.6% RoM)
Max Risk / Buffer -5.1% Cushion ($196 Mgn)
5d Edge & Liquidity 69% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Asymmetric 1x1x1 ($42.5C + $41/$38P)

+1x 11d $41P · -1x 38d $38P · +1x 32d $42.5C

Net Entry $141 Debit
T+5d @ +5% Move +$70 (+10.6% RoM)
Max Risk / Buffer -8.7% Put Cushion ($657 Mgn)
5d Edge & Liquidity 6.5x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NVO Moat Profile High-Margin Pricing Power Moat
Global GLP-1 Diabetes & Obesity Biologics Leader
Operates vertically integrated peptide fermentation and auto-injector supply chains serving global diabetes and weight-management markets.
OpEx & R&D Reinvestment 32.5% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ MBIO vs NVO Key Questions & Quantitative Answers

As of Nov 17, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas NVO carries 35.1/100 (SELL) at $41.60 (12.5x Forward P/E, 50.8% operating margin). Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. NVO 35.1/100 SELL), NVO captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (50.8% vs. 0.0% operating margin) and revenue trajectory (+5.6% vs. +0.0% YoY).

NVO leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NVO at +5.6% YoY revenue growth and -15.8% YoY earnings growth on $51.5B TTM revenue (83.3% gross margin, 50.8% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $51.5B for NVO. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus 32.5% of Rev ($16.7B) (0 disclosures) for NVO.

NVO screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NVO trades at 12.5x Forward P/E, 10.5x Trailing P/E, 4.31x PEG, and 3.8x EV/Revenue (13.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus NVO (58.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 87% Vol realized risk). By comparison, NVO carries 36.7% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.50β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.